180 Life Sciences (ATNF) Competitors $5.23 -1.81 (-25.71%) As of 08/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. LFVN, CYBN, ACTU, NKTX, NVCT, BIOA, DERM, GLSI, CRDF, and CLLSShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Lifevantage (LFVN), Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Journey Medical (DERM), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Lifevantage Cybin Actuate Therapeutics Nkarta Nuvectis Pharma BioAge Labs Journey Medical Greenwich LifeSciences Cardiff Oncology Cellectis 180 Life Sciences (NASDAQ:ATNF) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Is ATNF or LFVN more profitable? Lifevantage has a net margin of 4.12% compared to 180 Life Sciences' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -141.25% -80.77% Lifevantage 4.12%34.67%15.24% Do institutionals and insiders believe in ATNF or LFVN? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 38.2% of 180 Life Sciences shares are held by insiders. Comparatively, 20.7% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, ATNF or LFVN? Lifevantage has higher revenue and earnings than 180 Life Sciences. 180 Life Sciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$15.07-0.35Lifevantage$200.16M0.79$2.94M$0.6918.22 Which has more volatility & risk, ATNF or LFVN? 180 Life Sciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Do analysts prefer ATNF or LFVN? Lifevantage has a consensus target price of $30.50, suggesting a potential upside of 142.64%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts clearly believe Lifevantage is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ATNF or LFVN? In the previous week, 180 Life Sciences had 6 more articles in the media than Lifevantage. MarketBeat recorded 8 mentions for 180 Life Sciences and 2 mentions for Lifevantage. Lifevantage's average media sentiment score of 0.51 beat 180 Life Sciences' score of 0.21 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLifevantage beats 180 Life Sciences on 13 of the 15 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.58M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.3520.4330.4625.16Price / SalesN/A238.54392.5887.62Price / CashN/A42.3737.0358.50Price / Book1.807.918.956.21Net Income-$6.17M-$54.72M$3.26B$265.38M7 Day Performance-31.27%1.66%1.06%-1.13%1 Month Performance86.12%5.89%4.31%-0.71%1 Year Performance173.82%8.72%28.40%18.86% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences0.548 of 5 stars$5.23-25.7%N/A+278.5%$31.58MN/A-0.357Gap DownLFVNLifevantage4.0829 of 5 stars$13.69+1.5%$30.50+122.8%+47.4%$169.81M$222.35M19.84260News CoveragePositive NewsUpcoming EarningsCYBNCybin2.4601 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$166.55MN/A-1.5850Trending NewsAnalyst RevisionACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%-9.2%$166.22MN/A0.0010News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionNKTXNkarta2.0272 of 5 stars$2.35+0.9%$13.60+478.7%-55.8%$165.49MN/A-1.59140NVCTNuvectis Pharma3.781 of 5 stars$6.45+0.3%$15.33+137.7%-9.5%$163.69MN/A-5.518Positive NewsBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/ADERMJourney Medical1.7193 of 5 stars$7.00+0.7%$10.83+54.8%+58.9%$163.07M$56.40M-18.4290Analyst RevisionGLSIGreenwich LifeSciences1.428 of 5 stars$12.01-1.3%$39.00+224.7%-13.6%$162.69MN/A-8.833News CoverageEarnings ReportAnalyst ForecastCRDFCardiff Oncology1.6216 of 5 stars$2.43-0.4%$10.10+315.6%-0.9%$162.32M$680K-2.7920CLLSCellectis3.3286 of 5 stars$2.90+1.8%$4.00+37.9%+22.6%$158.41M$56.30M-3.54290Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies LFVN Competitors CYBN Competitors ACTU Competitors NKTX Competitors NVCT Competitors BIOA Competitors DERM Competitors GLSI Competitors CRDF Competitors CLLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access